The Food and Drug Administration approved the first epinephrine nasal spray for severe allergic reactions on Friday, August 9.
The drug, sold under the name “Neffy” by San Deigo-based ARS pharmaceuticals, is approved for severe allergic reactions for adults and children weighing 66 pounds and up.
Patients can expect to pay between $25 to $199 out of pocket for two single-use sprays, depending on their insurance coverage. Patient assistance programs may also be available for eligible individuals.
The FDA approval provides a needle-free alternative to epi pens, which some individuals may be hesitant to use, especially in cases of anaphylaxis.
RELATED STORY | Boy dies after eating strawberries bought from school fundraiser
Allergist Dr. Payel Gupta with the Allergy and Asthma Network stated, “That does, we know, delay treatment in individuals that are having an allergic reaction because those around them are nervous and are hesitant to use an injectable device.”
Symptoms of anaphylaxis include sudden hives, low blood pressure, difficulty breathing, a weak fast pulse, nausea, diarrhea, feeling dizzy, or fainting. Symptoms typically occur within minutes of exposure to the allergen that triggers the reaction, according to the Mayo Clinic.
The new epinephrine nasal spray is anticipated to be widely available within eight weeks.
RELATED STORY | FDA expands use of asthma drug Xolair to treat severe food allergies
